Appointment · 26 October 2026
XBiotech Inc.
XBIT · Listed
Key facts
- How the CEO left
- No departure described
- Planned or abrupt
- Planned
- Successor
- Internal (a current executive)
- Signs it was forced
- None stated
- Other news alongside
- None
- Effective
- 23 October 2026
- Reason given
- to realize the potential of our True-Human antibody therapies
Read from the filing and press release by a language model (Google Gemini), told to use only that text. It can make mistakes; the quotes below are the source.
The announcement
XBiotech, Inc. (“XBiotech” or the “Company”) announces that the Board of Directors has appointed Dr. Sushma Shivaswamy and Jan-Paul Simard to serve as Co-Chief Executive Officers of the Company effective October 23, 2026.
In December of 2025, Dr. Shivaswamy was named interim CEO following the retirement of Founder John Simard.
Sentences matched by our CEO change rules, from the first filing. Read the 8-K on SEC EDGAR ↗
Share price reaction
The filing reached SEC EDGAR on 26 October 2026 at 09:39 New York time, during trading hours, so day 0 is that same day. Day 0 is marked by the vertical line.
| Window | XBIT | S&P 500 | Abnormal |
|---|---|---|---|
| Days 0 to +1 | −4.1% | +1.3% | −4.7% |
| Days 0 to +3so far, 2 of 4 days | −4.1% | +1.3% | −4.7% |
| 1 month (days 0 to +21)so far, 2 of 22 days | −4.1% | +1.3% | −4.7% |
| 3 months (days 0 to +63)so far, 2 of 64 days | −4.1% | +1.3% | −4.7% |
The abnormal return is the stock's return beyond what its usual relationship with the market (beta 0.50) predicts. A single stock's move can reflect other news on the same days, so it describes what happened rather than measuring the effect of the CEO change; averages across many events are on the Research design page as they are completed.
News coverage
No matching headlines found. Coverage is thinner for smaller companies.